A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma

Biomed Res Int. 2022 Jun 16:2022:3742447. doi: 10.1155/2022/3742447. eCollection 2022.

Abstract

Glioma is one of the most common intracranial malignancies that plagues people around the world. Despite current improvements in treatment, the prognosis of glioma is often unsatisfactory. Necroptosis is a form of programmed cell death. As research progresses, the role of necroptosis in tumors has gradually attracted the attention of researchers. And lncRNA is regarded as a critical role in the development of cancer. Therefore, this study is aimed at establishing a prognostic model based on necroptosis-associated lncRNAs to accurately assess the prognosis and immune response of patients with glioma. The RNA sequences of glioma patients and normal brain samples were downloaded from The Cancer Genome Atlas (TCGA) and GTEx databases, respectively. The coexpression analysis was performed to identify the necroptosis-related lncRNAs. Then, we utilized LASSO analysis following univariate Cox analysis to construct a prognostic model. Subsequently, we applied the Kaplan-Meier curve, time-dependent receiver operating characteristics (ROC), and univariate and multivariate Cox regression analyses to assess the effectiveness of this model. And the functional enrichment analyses and immune-related analyses were employed to investigate the potential biological functions. A validation set was obtained from the Chinese Glioma Genome Atlas (CGGA) database. And qRT-PCR was employed to further validate the expression levels of selected necroptosis-associated lncRNAs. Seven necroptosis-related lncRNAs (FAM13A-AS1, JMJD1C-AS1, LBX2-AS1, ZBTB20-AS4, HAR1A, SNHG14, and LINC00900) were determined to construct a prognostic model. The area under the ROC curve (AUC) was 0.871, 0.901, and 0.911 at 1, 2, and 3 years, respectively. The risk score was shown to be an important independent predictor in both univariate and multivariate Cox regression analyses. Through functional enrichment analyses, we found that the differentially expressed genes (DEGs) were mainly enriched in protein binding and signaling-related biological functions and immune-associated pathways. In conclusion, we established and validated a novel necroptosis-related lncRNA signature, which could accurately predict the overall survival of glioma patients and serve as potential therapeutic targets.

MeSH terms

  • Biomarkers, Tumor / genetics
  • GTPase-Activating Proteins / genetics
  • Gene Expression Regulation, Neoplastic
  • Glioma* / genetics
  • Humans
  • Immunity
  • Jumonji Domain-Containing Histone Demethylases / genetics
  • Kaplan-Meier Estimate
  • Necroptosis / genetics
  • Oxidoreductases, N-Demethylating / genetics
  • Oxidoreductases, N-Demethylating / metabolism
  • Prognosis
  • RNA, Long Noncoding* / metabolism

Substances

  • Biomarkers, Tumor
  • FAM13A protein, human
  • GTPase-Activating Proteins
  • RNA, Long Noncoding
  • JMJD1C protein, human
  • Jumonji Domain-Containing Histone Demethylases
  • Oxidoreductases, N-Demethylating